Diagnostic and therapeutic challenges.
Murakami
Yoko
Y
Department of Ophthalmology, Osaka University Medical School, Suita, Japan.
Kusaka
Shunji
S
Oshima
Yusuke
Y
Tano
Yasuo
Y
Avery
Robert L
RL
Pieramici
Dante J
DJ
Arevalo
J Fernando
JF
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002199:Capillary Permeability; D003924:Diabetes Mellitus, Type 2; D003925:Diabetic Angiopathies / Q000188:drug therapy*; D003930:Diabetic Retinopathy / Q000150:complications*; D019793:Fluorescein / Q000493:pharmacokinetics; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008297:Male; D009389:Neovascularization, Pathologic / Q000150:complications / Q000188:drug therapy*; D009898:Optic Disk / Q000098:blood supply*; D018917:Optic Neuropathy, Ischemic / Q000139:chemically induced* / Q000175:diagnosis; D012163:Retinal Detachment / Q000150:complications*; D014786:Vision Disorders / Q000209:etiology* / Q000503:physiopathology; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D019793:Fluorescein